New to The Street, one of the leading U.S. business television platforms, announced the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company. The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.
As part of this extended partnership, Acurx Pharmaceuticals will be featured on New to The Street’s national television broadcasts. The series will spotlight the company’s latest developments, milestones, and its leadership in addressing critical bacterial infections through innovative antibiotics. The coverage will air across major networks, enhancing Acurx Pharmaceuticals‘ brand visibility and reputation within the biopharmaceutical sector.
In addition to broadcast television, the series will benefit from targeted earned media placements, amplifying exposure through high-visibility press outlets and digital media channels. Complementing the broadcast and earned media strategy, Acurx Pharmaceuticals will also receive support from New to The Street’s outdoor advertising platforms, including iconic billboard placements in strategic locations such as Times Square and the Financial District.
“We are thrilled to continue our collaboration with Acurx Pharmaceuticals as they progress in their mission to combat difficult-to-treat bacterial infections,” said Vince Caruso CEO of New to The Street. “Our multi-platform approach-combining national television, earned media, and outdoor campaigns-ensures their message reaches the right audience at scale.”
The media series is set to begin airing immediately, 2024, with outdoor and earned media elements running concurrently to maximize audience reach.
